Survodutide reduces body weight in Chinese adults with overweight or obesity
This phase 3 randomized controlled trial is designed to evaluate the efficacy, safety, and tolerability of survodutide (3.6 mg or 4.8 mg once weekly) versus placebo in Chinese adults with overweight or obesity. The primary endpoints are percentage change in body weight and achievement of ≥5% body weight reduction from baseline to week 52. Baseline characteristics show a mean BMI of 33.2 kg/m² and a high prevalence of obesity-related complications.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Survodutide reduces body weight in Chinese adults with overweight or obesity The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Survodutide reduces body weight in Chinese adults with overweight or obesity
This conclusion is most relevant to: Chinese adults with overweight or obesity (BMI ≥28 kg/m² or BMI ≥24 kg/m² with at least one obesity-related complication).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN). (Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026) —
How It Works
The proposed biological pathway:
- ▸Survodutide is a dual agonist of GLP-1 and glucagon receptors
- ▸It enhances insulin secretion and suppresses appetite
- ▸It increases energy expenditure via glucagon receptor activation
- ▸Result: Reduction in body weight
Who Might Benefit
Evidence fit by population:
- ▸Chinese adults with overweight or obesity (BMI ≥28 kg/m² or BMI ≥24 kg/m² with at least one obesity-related complication)
Recommended Dose
3.6 mg or 4.8 mg once weekly
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Baseline characteristics only; no efficacy or safety results reported yet
- ▸Trial is ongoing; final outcomes not available
- ▸Specific to Chinese population; generalizability to other ethnicities may be limited
Frequently Asked Questions
What is survodutide?▼
Survodutide is a dual agonist of GLP-1 and glucagon receptors, being investigated for weight management.
What are the primary endpoints of the SYNCHRONIZE-CN trial?▼
The primary endpoints are the percentage change in body weight and the proportion of participants achieving ≥5% body weight reduction from baseline to week 52.
Who is eligible for this trial?▼
Chinese adults with BMI ≥28 kg/m² or BMI ≥24 kg/m² with at least one obesity-related complication.
What is the duration of the trial?▼
The trial lasts 76 weeks, with primary endpoints assessed at week 52.
References
- 1.Ji L, Chen L, Cheng Z, Lu Y, Yang Y, Fu F, Zhu Y, Jin L, Kloer IM. “Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN)..” Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. PMID: 42599381 DOI: 10.1007/s13300-026-01908-x